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Abstract
Down-regulation of the KAI1 (CD82) metastasis suppressor is common in advanced human cancer, but underlying
mechanism(s) regulating KAI1 expression are only now being elucidated. Recent data provide evidence that low
levels of KAI1 mRNA in LNCaP cells are caused by binding of β-catenin/Reptin complexes to a specific motif in the
proximal promoter, which prevents binding of Tip60/Pontin activator complexes to the same motif, thus inhibiting
transcription. Here, we explored a pathway by which phorbol 12-myristate 13-acetate (PMA) up-regulates KAI1 tran-
scription in LNCaP prostate cancer cells. Pretreatment with specific inhibitors showed that induction of KAI1 by PMA
uses classic isoforms of protein kinase C (cPKC), is independent of Ras and Raf, and requires activation of MEK1/2
and ERK1/2, but does not involve p38MAPK. Induction of KAI1 transcription by PMA was associated with enhanced
overall acetylation of histones H3 and H4, but only acetylation of H3 was blocked by a PKC inhibitor. Chromatin im-
munoprecipitation showed that PMA induces recruitment of Tip60/Pontin activator complexes to NFκB-p50 motifs
in the proximal promoter, and this was blocked by a PKC inhibitor. These changes were not associated with differ-
ences in overall levels of Tip60, Pontin, β-catenin, or Reptin protein expression but with PMA-induced nuclear trans-
location of Tip60.
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Introduction
Down-regulated expression of the KAI1 metastasis suppressor is com-
mon in the advanced stages of many human cancer types [1,2]. Ex-
perimental studies using a combination of in vitro and in vivo
approaches have demonstrated that loss of KAI1 expression is associ-
ated with reduced homotypic cell adhesion, increased cell migration,
and altered ability of tumor cells to bind specific extracellular pro-
teins, such as fibronectin [3–5]. The consequences of these changes
are increased in vitro invasive [4,6,7] and in vivo metastatic [5,7] abil-
ity of tumor cells. Given this importance to tumor cell behavior, our
knowledge of factors regulating KAI1 expression is limited. Studies of
mechanisms underlying down-regulation in advanced cancers and
cancer cell lines have shown that loss of heterozygosity [8], mutations
in the KAI1 gene [8] and promoter hypermethylation [9,10] are un-
likely to be involved. Transient transfection approaches have iden-
tified several promoter regions important for basal transcription
[11] and have also provided evidence for the importance of a 76-bp
enhancer-like sequence upstream of the transcription start site in a
wide range of cancer cell types [12]. Other studies have linked tran-
scriptional regulation of KAI1 to changes in the composition of spe-
cific chromatin-remodeling protein complexes binding to a specific
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motif in the proximal KAI1 promoter [13,14]. Thus, in nonmet-
astatic cancer cells, activation of KAI1 transcription is mediated
by the binding of a Tip60/Pontin complex with associated histone
acetylase activity to a specific p50 motif in the proximal promoter.
In metastatic cancer cells, such as LNCaP prostate cancer cells,
Tip60/Pontin–mediated activation of KAI1 transcription is blocked
by an inhibitory complex consisting of β-catenin and Reptin recruit-
ing the histone deacetylase HDAC1 [14]. Currently, the relationship
between the p53, AP1, and AP2 proteins, which bind the enhancer,
and the role of the chromatin remodeling complexes to overall KAI1
transcription remain to be elucidated.
Biochemical pathways that determine transcriptional responses
of KAI1 to extracellular signals remain to be studied. Phorbol 12-
myristate 13-acetate (PMA) [15], nerve growth factor [16], tumor
necrosis factor alpha [17], and sodium butyrate (NaB) [18] all up-
regulate KAI1 mRNA levels in prostate cancer cells, which express
little or no KAI1 mRNA, but detailed signaling pathways used by
these factors have not been characterized. Because phorbol ester is
an established model for studying pathways used by growth factors
and hormones to regulate cell behavior, PMA was chosen as a starting
point to elucidate specific signaling pathways, which induce tran-
scription of KAI1. In addition, because previous studies have used
LNCaP prostate cancer cells to explore transcriptional regulation of
the KAI1 gene, we focused our studies on the effects of PMA in this
cell line. Results presented in this report show that PMA induced
KAI1 in LNCaP prostate cancer cells by activation of classic protein
kinase C (cPKC) isoforms. This up-regulation was Ras- and Raf-
independent and required activation of MEK/ERK signaling factors.
The data also provide support for the idea that PMA induces KAI1
transcription by recruiting a histone acetyl-transferase activator com-
plex of Pontin and Tip60 to specific motifs within the KAI1 pro-
moter region.
Materials and Methods
Chemicals and Reagents
Phorbol 12-myristate 13-acetate, AG126, BAPTA/AM, bis-
indolylmaleimide III (Bim III), bryostatin 1 (Bryo 1), FPT inhibitor
III, H89 dihydrochloride, PD98059, PP2, PP3, SB203580, stauros-
porine, thymeleatoxin, trichostatin A, and ZM336372 were from
Calbiochem (San Diego, CA). Actinomycin D, apigenin, 6-dichloro-
benzimidazole 1-β-D-ribofuranoside, and TriReagent were purchased
from Sigma-Aldrich (Castle Hill, NSW, Australia). U0126 was from
Cell Signaling Technology (Beverly, MA).
Tissue Culture
LNCaP were from Leland Chung (Department of Urology, Emory
University School of Medicine, Atlanta, GA) and cultured in T-
medium [19]. Media and supplements were all from Invitrogen
(Mount Waverley, Victoria, Australia). Cells were grown in a humid-
ified incubator at 37°C with 5% CO2. For experiments, LNCaP
cells (1 × 106) were seeded into 10-cm-diameter Petri dishes contain-
ing 10 ml of T-medium. After 24 hours, cells were pretreated with
inhibitors for 1 hour before exposure to 20 nM PMA for 6 hours.
Reverse Transcription–Polymerase Chain Reaction
Total RNA was isolated from cell cultures using TriReagent as per
manufacturer’s instructions. After phenol/chloroform extraction to
remove residual DNA, 2 μg RNA was used to prepare cDNA, as de-
scribed [6]. Forward and reverse primers for amplification of spe-
cific targets, together with sizes of amplified products, are shown in
Table 1. Reactions contained 2.5 μl of 10× reaction buffer, 0.25 μl
of 25 mM dNTP mix, 0.65 μl each of forward and reverse prim-
ers (20 pmol/μl), 1.0 μl of cDNA, 0.5 μl of Taq DNA polymerase
(5 U/ml), and 1.0 μl (KAI1) or 1.5 μl (GAPDH, Pontin, Reptin,
Tip60, and β-catenin) of 25 mM MgCl2, in a total volume of 25 μl,
and were performed in a Hybaid Touchdown Thermocycler (Hybaid
Limited, Basingstoke, United Kingdom). KAI1, Pontin, Reptin,
Tip60, and β-catenin were amplified at 94°C for 4 minutes, followed
by 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 sec-
onds, with a final step at 72°C for 10 minutes. Conditions were sim-
ilar for amplification of GAPDH, except that the elongation step
was extended to 45 seconds. In preliminary experiments, numbers
of cycles required to reach linear amplification for each product were
determined. Subsequently, the levels of expression for each gene in
control- or PMA-treated cells were examined in the middle of the
linear amplification phase (24 cycles, GAPDH; 25 cycles, Pontin,
Tip60 and β-catenin; 28 cycles, KAI1; 29 cycles, Reptin) to ensure
detection of increases or decreases in mRNA levels after drug treat-
ment. Reaction products were separated in 2.0% (w/v) agarose, visu-
alized with ethidium bromide and analyzed by Kodak Digital Science
1D Image Analysis Software (Eastman Kodak, Rochester, NY).
Graphically presented data show relative levels of expression (com-
pared with GAPDH) before and after treatment, expressed as mean ±
SE of at least three independent experiments. Where calculated, sta-
tistical significance was determined by Student’s t test, with confi-
dence levels indicated in the figure legends. Illustrated results are
representative of these experiments.
Western Blot Analysis
Total cell extracts were prepared by lysing cells in 250 μl M-Per
buffer (Pierce Endogen, Rockford, IL) containing 1× Protease In-
hibitor Cocktail 1 (5 μM AEBSF hydrochloride, 1.5 nM aprotinin,
10 nM E-64 protease inhibitor, 5 μM EDTA, and 10 nM leupeptin;
EMD Biosciences, San Diego, CA) with added sodium orthovanadate
(0.4 mM). Protein concentration of supernatants was determined by
BCA assay (Pierce Endogen). Extracts, containing 20 μg (p38MAPK,
MEK, ERK, β-catenin, and histones) or 50 μg (Tip60 and Reptin) of
protein, were separated in 7.5% (β-catenin), 10% (p38MAPK, MEK,
ERK,Tip60, Reptin), or 16% (acetylated histones) SDS–polyacrylamide
gels and transferred to nitrocellulose membranes. After blocking
with PBSTM [0.1% (v/v) Tween 20 in PBS (PBST) containing
5% (w/v) skimmed milk] for 1 hour at room temperature, filters
Table 1. Primer sequences used for RT-PCR.
Gene Amplicon Sequences (5′ to 3′)
KAI1 Forward 344bp CCCGGCAACAGGACCCAGAGT
KAI1 Reverse TCAGTCAGGGTGGGCAAGAGG
Tip60 Forward 184bp CAGGACAGCTCTGATGGAATA
Tip60 Reverse GAGGACAGGCAATGTGGTGAG
β-catenin Forward 298bp ACAACTGTTTTGAAAATCCA
β-catenin Reverse CGAGTCATTGCATACTGTCC
Pontin Forward 218bp GCATGTCGAAGAGATCAGTGA
Pontin Reverse CTGAACTGACAGCGCTGCA
Reptin Forward 239bp GAAATTGTCGAGGAACAAGAGAGT
Reptin Reverse TTTATTCAGGTAATTGAGCAGGTG
GAPDH Forward 600bp CCACCCATGGCAAATTCCATGGCA
GAPDH Reverse TCTAGACGGCAGGTCAGGTCCA
1422 Phorbol Ester Enhances KAI1 Transcription Rowe et al. Neoplasia Vol. 10, No. 12, 2008
were probed overnight at 4°C with the following specific anti-
bodies. Antibodies to total or phosphorylated forms of ERK1/2
(p44/p42) and p38MAPK, as well as HRP-conjugated secondary
antibodies, were from Cell Signaling Technology. Monoclonal anti-
bodies to acetylated histone H3 or H4 and Tip60 were from Upstate
(Charlottesville, CA) and to β-catenin (clone 14) from BD Bio-
sciences (Heidelberg, Germany). Rabbit polyclonal antibodies to
β-catenin (sc-7199) and tubulin (sc-1094) were from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse monoclonal and rabbit
polyclonal antibodies to human Reptin and Pontin have been de-
scribed previously [20–22]. After rinsing in PBST (3 × 5 minutes),
filters were incubated with an appropriate HRP-linked secondary
antibody for 1 hour at room temperature. After a final rinsing with
PBST (3 × 5 minutes) to remove unbound antibody, specific pro-
teins were visualized by the Supersignal WestPico (Pierce Endogen) or
Lumilight (Roche, Germany) chemiluminescence method and were
exposed to Fuji X-ray film or Hyperfilm (GE Healthcare, Freiburg,
Germany). Cytoplasmic and nuclear fractionation was performed as
previously reported [23] using the Nuclear Isolation Kit: Nuclei EZ Prep
(Sigma, Deisenhofen, Germany) according to the manufacturer’s rec-
ommendations except that nuclei were resuspended in RIPA buffer
[150mMNaCl, 25mMTris pH 6.8, 5 mMEDTA, 1% (w/v) sodium-
deoxcholate, 1% (v/v) NP-40, 0.1% (w/v) SDS]. Total lysates were gen-
erated in ice-cold lysis buffer [10 mM imidazole pH 6.8, 0.1 M KCl,
0.3 M sucrose, 2 mM MgCl2, 10 mM EGTA, 1 mM NaF, 1 mM
Na2MoO4, 1 mM NaVO3, 0.2% (v/v) Triton X-100, and complete
EDTA protease inhibitor cocktail].
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as de-
scribed previously [24] with minor modifications. LNCaP cells were
grown on 100-mm dishes to a confluence of 80% to 90%. At the
indicated times after the addition of 20 nM PMA, cells were washed
twice with PBS, fixed with 2 mM disuccinimidyl-glutarate for 45 min-
utes at room temperature, and then cross-linked for 10 minutes at
room temperature using 1% (v/v) formaldehyde. For inhibitor stud-
ies, cells were preincubated for 60 minutes with 10 μM Bim III be-
fore addition of PMA. In other control studies, cells were stimulated
with 5 ng/ml interleukin-1β (IL-1β) for the indicated times. For
immunoprecipitation, 2 μg of anti-NCoR (sc-1069; Santa Cruz Bio-
technology), 2 μg of anti–β-catenin (BD Biosciences), 2 μg of anti-
Tip60 (Upstate Biotechnology), 2 μg of anti-Reptin (L12E) [20],
and 5 μg of anti-Pontin (5G3-11) [22] antibodies were used. For
re-ChIP, the immunocomplexes were eluted with 100 μl of 10 mM
DTT at 37°C for 30 minutes and diluted at 1:40 in ChIP dilution
buffer followed by incubating with antibodies for the second immu-
noprecipitation. Second ChIP was performed as described for the
first immunoprecipitation. For subsequent polymerase chain reaction
(PCR) analysis, 2 μl of extracted DNA (50 μl) was used as template
for the amplification. Primers to detect the p50 binding motif in
the KAI1 proximal promoter have been previously described [14].
Polymerase chain reaction was performed using the following ampli-
fication parameters: an initial incubation of 2 minutes at 94°C was
followed by 32 cycles at 94°C for 15 seconds, annealing for 30 sec-
onds at 59°C, and elongation for 45 seconds at 72°C, with a final
extension for 3 minutes at 72°C. Polymerase chain reaction products
were separated on an 8% polyacrylamide gel, stained with ethidium
bromide, and subsequently analyzed under UV light.
Results
PMA Up-regulates KAI1 mRNA Levels in LNCaP Prostate
Cancer Cells
Initial experiments where mRNA levels were examined 24 hours
after treatment confirmed that PMA induced KAI1 in LNCaP cells
(Figure 1A). A significant induction was first observed with 2.5 nM
PMA, maximal (approximately three-fold) with 5.0 nM PMA, and
this level of induction was maintained with up to 20 nM PMA. At
Figure 1. Phorbol 12-myristate 13-acetate up-regulates KAI1mRNA
levels in LNCaP prostate cancer cells. (A) LNCaP cellswere untreated
(C), treated with DMSO vehicle only for 24 hours (V), or treated
with the indicated concentrations of PMA for 24 hours. KAI1 and
GAPDH mRNA levels were determined from total RNA by reverse
transcription–polymerase chain reaction (RT-PCR). (B) LNCaP cells
were treatedwithDMSO vehicle only (V) or treatedwith 20 nMPMA
for the indicated times. KAI1 and GAPDH mRNA levels were deter-
mined from total RNA by RT-PCR. Upper panels in (A) and (B) show
ethidium bromide–stained gels of representative data. Lower panels
show the relative levels of KAI1mRNA (KAI1/GAPDH) in treated cells.
Data represent themeans± SD of at least three independent experi-
ments. *P < .05, when compared with vehicle only–treated cells.
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40 nM PMA, the effect was decreased (Figure 1A). A time-course ex-
periment demonstrated that induction of KAI1 mRNA was first clearly
detectable from 4 hours after adding 20 nM PMA and that this increase
was statistically significant from 6 hours after addition (Figure 1B). A
maximal induction of approximately four-fold was observed 8 hours
after addition; thereafter, levels of KAI1 mRNA declined. On the basis
of these data, in subsequent experiments with inhibitors in LNCaP cells,
PMA was used at a concentration of 20 nM for 6 hours.
To determine whether this effect of PMA was generally applicable
to metastatic prostate cancer cells, we repeated these experiments
using DU145 and PC3 cells, both of which also express very low
levels of KAI1 mRNA. Data summarized in Figure W1 confirmed that
addition of PMA resulted in a dose-dependent induction of KAI1
mRNA levels in both DU145 and PC3 cells, with a maximum
1.5- to 3-fold induction at 8 (DU145) or 24 hours (PC3) after
the addition of 20 nM PMA. Although induction of KAI1 mRNA
by PMA was seen in all three prostate cancer cell lines tested, the
clearest induction was obtained using LNCaP cells. Subsequent
studies into the effects of PMA on KAI1 expression focused on the
LNCaP cell line, but similar results were obtained for both DU145
and PC3 cell lines (data not shown).
Classic Isoforms of Protein Kinase C Directly Mediate
Up-regulation of KAI1 mRNA by PMA
Phorbol 12-myristate 13-acetate mediates its effects by mimicking
diacylglycerol (DAG), the endogenous activator of protein kinase C
(PKC). Pretreatment of LNCaP cells for 1 hour with 10 μM Bim III,
a highly selective cell-permeable PKC inhibitor, had no effect on low
basal levels of KAI1 mRNA but completely blocked induction of
KAI1 by PMA (Figure 2A). Pretreatment of LNCaP cells with two
less-specific inhibitors of PKC, staurosporine (250 nM) and apigenin
(50 μM), also completely blocked induction of KAI1 by PMA (Fig-
ure 2A). In contrast, pretreatment of cells with H-89 dihydrochloride
(10 μM), a potent and specific inhibitor of protein kinase A or
with the casein kinase II inhibitor 6-dichloro-benzimidazole 1-β-D-
ribofuranoside (25 μg/ml) did not markedly affect basal levels of
KAI1 or prevent up-regulation of KAI1 by PMA (Figure 2B). Simi-
larly, the Src-dependent tyrosine kinase inhibitor PP2 (5 nM) had
no effect on the induction of KAI1 by PMA (Figure 2C ). PP3, a
negative control for PP2 and a potent inhibitor of epidermal growth
factor receptor kinase, failed to prevent induction of KAI1 by PMA.
These data suggested that PKC was directly mediating up-regulation
of KAI1 mRNA by PMA in prostate cancer cells.
The PKC family consists of 12 serine-threonine kinases divided
into three major groups: classic (α, β, and γ), novel (δ, ɛ, η, and
θ), and atypical (μ, ξ, and ι). Activation of classic enzymes requires
calcium and DAG, novel enzymes are activated by DAG, and atyp-
ical forms are activated independently of calcium or DAG [25]. In-
volvement of specific PKC enzymes in the induction of KAI1 by
PMA was tested using an endogenous calcium-chelator (BAPTA/
AM; 25 μM) or apigenin (50 μM) and then adding PMA (20 nM).
Pretreatment of cells for 1 hour with BAPTA/AM blocked induction
of KAI1 by PMA as efficiently as apigenin (Figure 2D), suggesting
that cPKC mediated the effect of PMA. To test this possibility, cells
were pretreated for 1 hour with BAPTA/AM or apigenin, and then
for 6 hours with Bryo 1 (50 nM) or thymeleatoxin (50 nM), which
specifically activate cPKC enzymes. Thymeleatoxin up-regulated
KAI1 as effectively as PMA and this was blocked by apigenin and
BAPTA/AM (Figure 2D). In contrast, Bryo 1 had little effect on
KAI1 mRNA levels (Figure 2D). A possible explanation for this dis-
crepancy can be proposed from results of previous studies that have
reported that although Bryo 1 activates cPKC enzymes [26], long-
term exposure (>4 hours, as in the present study) can dramatically
and specifically down-regulate cPKCα [27,28]. These data suggested
that induction of KAI1 by PMA in prostate cancer cells is mediated
by a calcium-dependent cPKC enzyme and that the specific isoform
responsible is possibly cPKCα.
PKC Directly Activates MEK and ERK1/2 in Up-regulation of
KAI1 mRNA by PMA
Downstream targets of PKC activation by PMA can use either
Ras-dependent [29–31] or Ras-independent [32–34] signaling path-
ways. To assess the role of Ras in the induction of KAI1 by PMA,
LNCaP cells were pretreated with a potent inhibitor of the Ras
farnesyl protein transferase that blocks activation of Ras (FPT III;
50 μM). FPT III had little effect on basal levels of KAI1 or on the
induction of KAI1 by PMA (Figure 2E ). The involvement of down-
stream effector molecules in the signaling pathway was first tested
with ZM 336372 (100 nM), a selective and potent inhibitor of
c-Raf. Again, pretreatment of cells with this inhibitor failed to block
induction of KAI1 by PMA (Figure 2E). To investigate the importance
of alternative signaling pathways downstream of c-Ras, cells were first
pretreated with either PD98059 (75 μM) or U0126 (5 μM) to selec-
tively block MEK1/2. As a control, we used SB203580 (2 μM), a
highly specific inhibitor of p38MAP kinase. PD98059 and U0126
inhibitors each had little effect on basal levels of KAI1 mRNA but
completely blocked induction of KAI1 mRNA by PMA (Figure 2E).
Conversely, SB203580 did not block induction of KAI1 mRNA by
PMA (Figure 2E ). Effects of the MAP kinase inhibitors were con-
firmed by Western blot analysis with antibodies to either total
ERK1/2 or p38MAPK or with antibodies specific for phosphorylated
activated forms of these proteins. Results shown in Figure 2F verified
that ERK1 (p44), ERK2 (p42) and p38MAPK were present in un-
treated LNCaP but that no detectable phosphorylated protein was
present. Phorbol 12-myristate 13-acetate had no effect on total levels
of p44 or p42 but caused some reduction in p38MAPK by 60 minutes
of treatment. ERK proteins (particularly p42) were phosphorylated
by 15 minutes after treatment with 20 nM PMA. Phosphorylated
p42 was still present 60 minutes after the addition of PMA, but the
levels of phosphorylated p44 were decreased by 45 minutes after add-
ing PMA and not detectable by 60 minutes. Importantly, phosphor-
ylation of p44 and p42 was completely blocked by pretreatment of
cells with 5 μM U0126. In contrast, there was no phosphorylation
of p38MAPK by PMA (Figure 2F ), lending further support to the
notion that a signaling pathway involving this protein is not involved
in the induction of KAI1 by PMA and providing an explanation for
the failure of SB203580 to block induction (Figure 2E). The impor-
tance of ERK1/2 to the induction of KAI1 by PMA was then tested
using AG126 (100 μM), an inhibitor of the ERK2 tyrosine kinase
(Figure 2F ). This inhibitor completely abrogated the effect of PMA
on KAI1. In summary, these data suggested that the pathway of
KAI1 induction by PMA involved direct signaling from PKC through
MEK1/2 and ERK1/2.
Up-regulation of KAI1 mRNA by PMA Involves
Histone Acetylation
Depending on the stimulus, downstream effectors of ERK1/2 ac-
tivation target either protein translation or transcription (reviewed in
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Figure 2. Phorbol 12-myristate 13-acetate uses a classic PKC isoform–dependent, Raf-independent pathway involving MEK1/2 and
ERK1/2 for induction of KAI1/CD82 mRNA. Reverse transcription–polymerase chain reaction analysis of RNA from LNCaP cells pre-
treated for 1 hour with the indicated concentrations of PKC inhibitors (A), PKA and CKII inhibitors (B), Src tyrosine kinase inhibitors (C),
specific PKC activators (D), and specific Ras downstream pathway inhibitors (E) before the addition of 20 nM PMA for 6 hours. Cells were
harvested, then RNA-isolated, converted to cDNA and used in PCR analyses for KAI1 and GAPDH, as described in the Materials and Meth-
ods section. Graphs show relative levels of KAI1 (KAI1/GAPDH). Data are means ± SE of at least three independent experiments. (F) LNCaP
cells were treated with 20 nM PMA for the indicated periods; 20 μg per lane of total protein cell lysate was subjected to electrophoresis,
blotted to nitrocellulose membrane, and then probed for nonphosphorylated and phosphorylated forms of ERK1/2 and p38MAPK, as in-
dicated. In lane 30U*, as a control, cells were pretreated for 1 hour with U0126 before addition of PMA. Lanes labeled * for p38MAPK and
phospho-p38MAPK, show signal generated by positive control lysates to verify antibodies were effective.
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Hazzalin and Mahadevan [35]). Consistent with a previous study
[15], pretreatment of cells with actinomycin D or cycloheximide be-
fore the addition of PMA clearly blocked the induction of KAI1, im-
plying a role for de novo transcription and translation in the effects of
PMA (not shown). Furthermore, ERK1/2–dependent up-regulation
of transcription can involve altered chromatin structure (for example,
[36,37]; reviewed in Clayton and Mahadevan [38]). Chromatin im-
munoprecipitation has provided compelling evidence for the impor-
tance of chromatin remodeling complexes binding a specific NF-κB
(p50) motif in the proximal promoter [14] to KAI1 transcription
(summarized in Figure 3A). In nonmetastatic cells, IL-1β–dependent
activation of the KAI1 promoter involves displacement of an NCoR-
repressor complex by an activator complex of Tip60 and Pontin
(which acetylates histones H3 and H4). Although the NCoR com-
plex is displaced in metastatic LNCaP cancer cells treated with IL-1β,
subsequent binding of the Tip60/Pontin activator complex is blocked
by a repressor complex containing β-catenin and Reptin, which in-
hibits transcription by recruiting HDAC1 [14].
A role for HDAC1 in suppressing KAI1 transcription is supported
by previous studies showing that NaB [18] and trichostatin A [10]
can elevate KAI1 mRNA levels. Induction of KAI1 mRNA by NaB
(data not shown) and trichostatin A was confirmed in LNCaP cells
(Figure 3B). Induction occurred within a time frame (first detected
4-6 hours after drug addition) similar to that of PMA (Figure 3C )
and was accompanied by overall acetylation of histones H3 and
H4 (Figure 3D). H3 and H4 were also strongly acetylated in LNCaP
cells from 30 minutes after the addition of 20 nM PMA (Figure 3, E
and F ). Acetylation of H3 was maximal at 1 hour, remained elevated
2 to 4 hours after addition, but declined to near basal levels by
6 hours (Figure 3E ). Acetylation of H4 was maximal 2 to 4 hours
after the addition of PMA but still elevated 6 hours after addition
(Figure 3F ). Acetylation of H3 by PMAwas blocked by pretreatment
of the cells with the PKC inhibitor, apigenin (Figure 3G ), but acet-
ylation of H4 by PMA was not blocked by either apigenin (Fig-
ure 3G ) or U0126 (data not shown), suggesting that the effect of
PMA on histone H4 acetylation might be not specific to the PKC
activation pathway described previously. Confirming the importance
of histone H3 acetylation to KAI1 transcription, thymeleatoxin, an-
other inducer of KAI1, which acts through cPKC (Figure 2D), also
clearly stimulated overall acetylation of histone H3 over a time course
similar to that of PMA but only weakly affected acetylation of H4
(Figure 3H ).
Together, these data were consistent with a model whereby PMA
activates KAI1 transcription in LNCaP cells through a signaling
pathway, which directly results in increased acetylation of cellular
H3 and is associated with acetylation of H4. However, this does
not imply that histone acetylation directly contributes to the up-
regulation of KAI1 transcription by phorbol ester.
PMA Recruits Specific Activator Protein Complexes to the
KAI1 Promoter
Given these results and data from preliminary experiments using
the inhibitor anacardic acid, which suggested that p300 and PCAF
were not the histone acetyltransferases targeted by PMA to induce
KAI1 (data not shown), ChIP was used to assess binding of p50, re-
pressor (NCoR, β-catenin, Reptin), and activator (Pontin and Tip60)
complexes to the p50 binding motif identified by Kim et al. [14] and
Baek et al. [39] in vehicle-treated LNCaP cells and cells treated with
20 nM PMA. Association of these proteins in response to PMA was
compared with their binding to the p50 motif in response to IL-1β
treatment (5 ng/ml) for the indicated times). Results illustrated in
Figure 4A (top left panel ) show that in untreated LNCaP cells, NCoR
and p50 bind this motif. Consistent with Kim et al. [14], treatment
with IL-1β resulted in displacement of NCoR but not p50 within
0.5 hours of IL-1β addition and in recruitment of β-catenin and
Reptin to the promoter (Figure 4A, top right panel ). By 2 hours
after the addition of IL-1β, both β-catenin and Reptin had been
displaced again and NCoR reappeared on the promoter, thereby
keeping the promoter in the inactive state. There was no evidence
for binding of the activator proteins Tip60 or Pontin to the pro-
moter at any time after the addition of IL-1β. NCoR, but not p50,
was also lost from the promoter after the addition of 20 nM PMA
(Figure 5A, lower left panel ), but the kinetics of this loss was slower
than that observed for IL-1β, with NCoR taking 2 hours to be com-
pletely lost from the promoter. In the absence of NCoR, β-catenin
and Reptin appeared on the promoter 2 hours after the addition of
PMA. In contrast to the response to IL-1β, Tip60 and Pontin also
appeared on the promoter at this time after PMA addition. All
four proteins were still present 4 hours after the addition of PMA,
but after 6 hours, Reptin had been lost from the promoter, Tip60
levels were decreasing, and NCoR had reappeared, suggesting that
the promoter was returning to an inactive state. Importantly, these
effects caused by PMA were significantly delayed by pretreating cells
with the PKC inhibitor Bim III (Figure 4A, lower right panel ), pro-
viding evidence that the PKC signaling pathway described was re-
sponsible for mediating PMA-dependent changes in proteins binding
the KAI1 promoter.
A two-step ChIP approach was then used to assess the composi-
tion of complexes binding the KAI1 promoter at 1 hour after the
addition of IL-1β and 4 hours after the addition of PMA. These
studies confirmed that complexes binding the promoter after the ad-
dition of IL-1β were composed of β-catenin and Reptin (Figure 4B,
lanes 1-7 ) as described previously [14]. At 4 hours after the addition
of PMA, β-catenin, Reptin, Tip60, and Pontin are all detected on
the KAI1 promoter (Figure 4A). However, these data cannot deter-
mine whether all four proteins are bound to the same promoter or
whether proteins forming a repressor complex (β-catenin and Reptin)
are on different promoters to those proteins that form an activa-
tor complex (Tip60 and Pontin). Data in Figure 4B (lanes 8-22)
show that, also in response to PMA, Reptin forms complexes only
with β-catenin and not with Pontin or Tip60 (lanes 11-14 ). Fur-
thermore, no interaction between β-catenin and Tip60 was detected
when β-catenin was on the promoter (lane 21). In contrast, if Pontin
was present on the promoter, only complexes with Tip60 were
detected (lanes 15-18). These data were in agreement with those of
Kim et al. [14] who showed that binding of β-catenin and Reptin
complexes, or Pontin and Tip60 complexes to the KAI1 promoter
is mutually exclusive. Our studies suggested that 4 hours after the
addition of PMA, a proportion of KAI1 promoters in the treated cell
population had recruited Tip60/Pontin activator complexes to the
KAI1 promoter.
PMA Induces Nuclear Translocation of Tip60
Changing relative levels of Tip60, β-catenin, or Reptin by overex-
pression of Tip60 or down-regulation of β-catenin or Reptin is suf-
ficient to restore IL-1β–dependent acetylation of histones H3 and
H4 and, consequently, activation of the KAI1 promoter in LNCaP
cells by favoring formation of Tip60/Pontin activator complexes
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Figure 3. Trichostatin A and PMA induce acetylation of H3 and H4 histones in LNCaP cells. (A) Schematic of the proposed arrangement
of Tip60 or β-catenin containing complexes on the KAI1 promoter, in nonmetastatic and metastatic cancer cells, before and after stim-
ulation with IL-1β. Diagram modified from Kim et al. [14]. (B) Polymerase chain reaction analysis of KAI1 and GAPDH levels in LNCaP
treated for 24 hours with DMSO vehicle or with 100 ng/ml trichostatin A in DMSO (TA). Graph shows relative levels of KAI1 (KAI1/
GAPDH). Data are means ± SE of at least three independent experiments. (C) Polymerase chain reaction analysis of KAI1 and GAPDH
in LNCaP treated for up to 24 hours with 100 ng/ml trichostatin A in DMSO. Vehicle-treated cells (V) were exposed to DMSO only for
24 hours. Graph summarizes mean ± SE from four independent experiments. *P < .05 compared with vehicle-only control. (D) Western
blot analysis of acetylated histones H3 and H4, in lysates from LNCaP cells treated for 8 hours with DMSO vehicle (−) or 100 ng/ml
trichostatin A (TA; +). (E, F) Western blot analysis of acetylated H3 (E) and H4 (F) histones in lysates from LNCaP cells treated with 20 nM
PMA for the indicated times. (G) Western blot analysis for acetylated histones H3 and H4 in LNCaP cells after a 1-hour exposure to
20 nM PMA either without (−) or with (+) 1 hour of pretreatment with 50 μM apigenin. (H) Cells were treated with 50 nM thymeleatoxin
for the indicated times, and lysates were used for Western blot analysis of acetylated histones H3 and H4 as described in the Materials
and Methods section.
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on the KAI1 promoter [14]. To determine whether PMA-induced
changes in relative levels of these proteins might underlie the ob-
served changes in the composition of protein complexes binding
to the p50 motif in the KAI1 promoter, mRNA and protein levels
for Tip60, β-catenin, Reptin, and Pontin were examined in cells
treated with 20 nM PMA for up to 6 hours. Data presented in
Figure 5 show that mRNA (Figure 5A) and protein levels (Figure 5B)
for Tip60, β-catenin, Pontin, and Reptin were unchanged by PMA,
whereas KAI1 mRNA levels were clearly elevated by 4 hours after the
addition of PMA. Not only Pontin and Reptin but also Tip60 and β-
catenin are proteins that have been localized both in the cytoplasm
and nucleus (see, for example, control samples in Figure 5C ), but the
fraction of these proteins within the nucleus is responsible for their
effects on transcription. In the absence of any PMA-dependent
changes in the overall expression of these proteins, the observed ef-
fects might be explained by an altered intracellular distribution of
one or more of these proteins in response to PMA; specifically, an
increase in the levels of Tip60 and Pontin within the nucleus. To
address this possibility, LNCaP cells were stimulated with PMA,
and at different time points after the addition of PMA, cytosolic
Figure 4. Phorbol 12-myristate 13-acetate induces changes in the composition of chromatin-remodeling protein complexes at specific
NFκB-p50 sites in the promoter of the KAI1 gene. (A) LNCaP cells were either treated with DMSO vehicle, 5 ng/ml IL-1β, and 20 nM PMA
for 1 hour or treated with 10 μM Bim III before 20 nM PMA for the indicated times and then processed for ChIP analysis of proteins
binding to the KAI1 promoter, as described in the Materials and Methods section. Data are representative of two independent experi-
ments. (B) Samples from (A) were subsequently analyzed by two-step ChIP to determine interactions between specific proteins binding
the KAI1 promoter in cells treated with PMA for 1 and 4 hours.
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Figure 5. Expression of chromatin remodeling proteins in the 6 hours after the addition of PMA. (A) Reverse transcription–polymerase
chain reaction analysis of KAI1, Tip60, Pontin, β -catenin, Reptin, and GAPDHmRNA levels in control LNCaP cells (C), vehicle only–treated
LNCaP cells (V), and LNCaP cells treated for 0 to 6 hours with 20 nM PMA. Graph shows relative expression of each gene compared with
GAPDH in control and treated cells. Data are means ± SE of at least three independent experiments. (B) Western blot analysis of Tip60,
β-catenin, Pontin, Reptin, and β-actin protein levels in LNCaP cells treated for 0 to 6 hours with DMSO or with 20 nM PMA in DMSO. Cells
were lysed in RIPA buffer and 25 μg of protein was loaded per lane. (C) Cells were treated with PMA as in (B), and cytoplasmic and nuclear
fractionations were analyzed for Tip60, β-catenin, Pontin, and Reptin by Western blot analysis. Protein loading was controlled with anti–
lamin A/C and anti-GAPDH antibodies. Data are representatives of three independent experiments.
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and nuclear fractions were analyzed for the expression of Tip60, β-
catenin, Pontin, and Reptin by Western blot analysis. Interestingly,
there was a rapid loss of Tip60 from the cytosolic fraction (detectable
by 30 minutes after the addition of PMA) and a concomitant accu-
mulation of Tip60 within the nuclear fraction (Figure 5C ). This dis-
tribution was maintained for up to 6 hours after the addition of PMA
(Figure 5C ). In contrast, the distribution of β-catenin, Pontin, and
Reptin between the cytoplasm and nucleus was not altered after the
addition of PMA. These data overall suggested that increasing nu-
clear levels of Tip60 may be responsible for changes in the compo-
sition of protein complexes binding the KAI1 promoter associated
with induction of transcription by PMA, by favoring the formation
of Tip60/Pontin activator complexes.
Discussion
We have characterized a signaling pathway and downstream mo-
lecular events used by PMA to induce the expression of the KAI1
metastasis-suppressor gene in LNCaP prostate cancer cells. Consis-
tent with the current understanding of signaling pathways involving
PMA, induction of KAI1 occurred through a pathway, which used
classic isoforms of protein kinase C and directly activated MEK
and ERK intermediates. Whereas signaling pathways used by PMA
generally involve both Ras- and Raf-dependent steps (see Ming et al.
[33]), in this study, the use of inhibitors suggested no requirement
for either of these intermediates. Other studies have shown that PKC
can bypass Ras and directly activate Raf [34,40,41]. Additionally, in
certain cell types and for certain responses, Ras and Raf may both be
bypassed. Thus, a combination of specific inhibitors and overexpres-
sion of dominant-negative proteins has been used to show that the
pathway of PMA-induced growth arrest in HepG2 cells requires
PKCα and ERK but not Ras or Raf [42]. Similarly, growth arrest
of Bcr/Abl–transformed leukemia cells by perillyl alcohol can occur
by directly inhibiting MEK signaling and bypass of both Ras and
Raf [43]. Whereas our studies support the idea that PMA activates
a cPKC-MEK/ERK–dependent signaling pathway resulting in the
up-regulation of KAI1 transcription, we cannot exclude the possibil-
ity that more global effects of PMA on cellular metabolism may also
contribute to the overall effects of PMA on KAI1 mRNA levels. Con-
sistent with this possibility, pretreatment of cells with translational
inhibitors such as cyclohexamide also partially inhibited induction
of KAI1 mRNA by PMA.
Recent studies have demonstrated the importance of specific pro-
tein complexes containing β-catenin, Reptin, Pontin, and Tip60
binding to a specific NFκB-p50 motif in the proximal promoter reg-
ulating KAI1 transcription in response to IL-1β [13,14]. Data from
the present study suggest that this p50 motif is also a key element in
regulating the transcriptional response to PMA. The chromatin re-
modeling components mediating the response to PMA are similar
to those involved in the response to IL-1β. However, whereas NCoR
is completely replaced by β-catenin/Reptin repressor complexes in
LNCaP cells exposed to IL-1β, thus preventing the binding of acti-
vator complexes containing Pontin and Tip60, the displacement of
NCoR in response to PMA results in the binding of Tip60/Pontin
complexes at least to a proportion of promoters within the cell popu-
lation, resulting in transcriptional activation. The kinetics of changes
in proteins binding to the KAI1 promoter in response to PMA treat-
ment, however, suggested that transcriptional regulation of KAI1 is
complex. At the moment, we cannot explain how the assembly of
β-catenin/Reptin complexes and reappearance of NCoR at the NFκB
site on the KAI1 promoter, within the first 6 hours after PMA treat-
ment, can be correlated with an overall increase of KAI1 mRNA from
6 to 24 hours after the addition of PMA. Currently, we are consid-
ering three possible mechanisms to explain this phenomenon, which
may act together to regulate the KAI1 promoter. 1) In addition to the
specific site investigated in this paper, other regulatory cis-elements
may contribute to the observed changes of mRNA levels induced
by PMA; for example, the upstream enhancer-like motif containing
p53, AP1, and AP2 motifs identified by Marreiros et al. [44]. 2) Re-
cruitment of additional unidentified factors may be involved in the
regulation at the site investigated in the present study and/or addi-
tional sites. 3) Recent observations report that transcription is regu-
lated by a highly dynamic assembly/disassembly of protein complexes
at regulatory cis-elements at gene promoters with cycles of association
and dissociation of regulatory factors [45,46]. Further studies will be
required to clarify the importance of these different elements.
The underlying basis for a lack of transcriptional response to IL-1β
in metastatic cells, such as LNCaP cells, is proposed to be due, at
least in part, to very low levels of Tip60 relative to β-catenin in these
cells, thus favoring formation of repressive β-catenin/Reptin com-
plexes [14]. This model suggests that one possible mechanism by
which PMA might allow formation of Tip60/Pontin complexes on
the promoter is by changing relative levels of Tip60 and β-catenin,
such that the chances of a Tip60/Pontin complex binding the pro-
moter are increased. Although examination of the overall expression
of these four proteins after the addition of PMA provided no evi-
dence to support this proposal, we did observe that PMA caused a
rapid and specific redistribution of Tip60 from the cytoplasm to the
nucleus. Increased levels of Tip60 would favor the chances of Tip60
binding the promoter. Further studies will need to define whether
PKC and/or MEK/ERK signaling is responsible for the nuclear trans-
location of Tip60 caused by PMA and how activation of PKC and/or
MEK/ERK signaling specifically affects transcription, for example,
which proteins are being affected by phosphorylation induced by this
pathway, and how signaling induced by IL-1β induces different ef-
fects on proteins binding the KAI1 promoter.
How might PMA promote binding of Tip60 and Pontin to the
regulatory site in the KAI1 gene in LNCaP cells? Recent reports in-
dicate a role of sumoylation/desumoylation during prostate cancer
development and metastasis [47,48]. A recent study has shown that
metastatic cells express higher levels of the small ubiquitin-like mod-
ifier (SUMO)–conjugating enzyme Ubc9, which attaches SUMO to
Reptin, and lower levels of SUMO-processing enzymes, such as
SENP1 and SUSP1 [13]. SUMOylation stimulates the repressive
effects of Reptin by promoting nuclear localization and increasing
interaction with HDAC1 [13]. Levels of SUMOylated repressive
Reptin are higher in metastatic than in nonmetastatic cells, and this
form of Reptin prevents binding of Tip60 to the KAI1 promoter
[13]. Conceivably, PMA might favor formation of Tip60/Pontin
complexes on the KAI1 cis-regulatory element by de-SUMOylating
Reptin or promoting SUMOylation of Pontin [49]. Despite exhaus-
tive attempts, we were unable to convincingly show the presence
of any SUMOylated Reptin or Pontin in this study (data not shown).
In ChIP experiments, with anti-SUMO antibodies, it was possible
to detect binding of a SUMOylated component/s to the KAI1 pro-
moter (not shown), but cross-linking during ChIP experiments
does not allow specific identification of the SUMOylated compo-
nent. In addition, it was not possible to completely correlate changes
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in SUMOylation with the time-dependent changes in the complex
composition at the cis-regulatory sites observed in the ChIP experi-
ments, even when assuming that Reptin and Pontin are the only can-
didates to be SUMOylated (data not shown). Interestingly, only a
small fraction (5%) of the overall Reptin population is SUMOylated,
yet more than a third of the total pool is nuclear [50]. This has raised
questions as to why the non-SUMOylated Reptin in the nucleus
does not normally compete with SUMOylated Reptin for binding
to the KAI1 promoter to activate transcription [50]. It will be impor-
tant to determine whether PMA has any effect on the proportion of
SUMOylated Reptin or Pontin associated with the KAI1 promoter.
A third mechanism by which the transcriptional activity of Pontin
and Reptin can be modulated has been recently described [22]. Hint 1
(histidine triad nucleotide-binding protein 1) binds both Pontin and
Reptin, and it was shown to disrupt Pontin/Reptin complexes and thus
may contribute to the formation of Pontin/Tip60 or β-catenin/Reptin
transcriptional complexes. Because Hint1 was previously identified as
PKC interacting protein-1 (PKCI-1), it can be speculated that PKC
through Hint1 may affect the transcriptional output at target gene pro-
moters [51]. It is intriguing to speculate that PKC-dependent phos-
phorylation of Tip60 might be involved in its accumulation in the
nucleus or in enhancing of the binding of Tip60 to Pontin.
Taken together, our data and the increased expression and en-
hanced nuclear localization of Pontin and Reptin observed in cancer
tissues [52–54] suggest that an exact regulation of nuclear Tip60/
Pontin and β-catenin/Reptin levels and function is important for
the transcriptional output at KAI1 and perhaps other promoters.
However, the molecular mechanisms have to be further investigated
in vitro and in vivo [55], and their general role in the metastasis of
tumor cells of other origins such as breast or colon remains to be
examined. In this context, here, we have identified a signaling path-
way by which PMA up-regulates KAI1 transcription by stimulating
the formation of specific activator complexes on the KAI1 promoter.
These data provide further support for the central importance of the
Reptin/β-catenin: Tip60/Pontin axis in regulating gene expression.
References
[1] Liu WM and Zhang XA (2006). KAI1/CD82, a tumor metastasis suppressor.
Cancer Lett 240, 183–194.
[2] Tonoli H and Barrett JC (2005). CD82 metastasis suppressor gene: a potential
target for new therapeutics? Trends Mol Med 11, 563–570.
[3] Jee B, Jin K, Song HG, and Lee H (2003). Metastasis-suppressor KAI1/CD82
induces homotypic aggregation of human prostate cancer cells through a Src-
dependent pathway. Exp Mol Med 35, 30–37.
[4] Takaoka A, Hinoda Y, Satoh S, Adachi Y, Itoh F, and Adachi M (1998). Sup-
pression of invasive properties of colon cancer cells by a metastasis suppressor
KAI1 gene. Oncogene 16, 1443–1453.
[5] Yang JL, Jackson P, Yu Y, Yoshie O, Ham JL, Russell PJ, and Crowe PJ (2001).
Invasion and metastasis correlate with down-regulation of KAI1 expression in
human colon cancer cell lines. GI Cancer 3, 313–322.
[6] Jackson P, Kingsley EA, and Russell PJ (2000). Inverse correlation between KAI1
mRNA levels and cell hehaviour in bladder cancer cell lines. Cancer Lett 156,
9–17.
[7] Yang X, Wei LL, Tang C, Slack R, Mueller S, and Lippman ME (2001). Over-
expression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in
breast cancer cells. Cancer Res 61, 5284–5288.
[8] Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, and
Isaacs JT (1996). Down-regulation of the KAI1 metastasis suppressor gene dur-
ing the progression of human prostatic cancer infrequently involves gene muta-
tion or allelic loss. Cancer Res 56, 4387–4390.
[9] Jackson P, Millar D, Kingsley E, Yardley G, Ow K, Clark S, and Russell PJ
(2000). Methylation of a CpG island within the promoter region of the KAI1
metastasis suppressor gene is not responsible for down-regulation of KAI1 expres-
sion in invasive cancer cell lines. Cancer Lett 157, 169–176.
[10] Sekita N, Suzuki H, Ichikawa T, Kito H, Akakura K, Igarashi T, Nakayama T,
Watanabe M, Shiraishi T, Toyota M, et al. (2001). Epigenetic regulation of the
KAI1 metastasis suppressor gene in human prostate cancer cell lines. Jpn J Can-
cer Res 92, 947–951.
[11] Gao AC, Lou W, Dong JT, Barrett JC, Danielpour D, and Isaacs JT (2003).
Defining regulatory elements in the human KAI1 (CD82) metastasis suppressor
gene. Prostate 57, 256–260.
[12] Marreiros A, Czolij R, Yardley G, Crossley M, and Jackson P (2003). Identifi-
cation of regulatory regions within the KAI1 promoter: a role for binding of
AP1, AP2 and p53. Gene 302, 155–164.
[13] Kim JH, Choi HJ, Kim B, Kim MH, Lee JM, Kim IS, Lee MH, Choi SJ, Kim
KI, Chung CH, et al. (2006). Roles of sumoylation of a reptin chromatin-
remodelling complex in cancer metastasis. Nat Cell Biol 8, 631–639.
[14] Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C, Chen C, Chung CH,
Huber O, Rose DW, et al. (2005). Transcriptional regulation of a metastasis
suppressor gene by Tip60 and β-catenin complexes. Nature 434, 921–926.
[15] Akita H, Iizuka A, Hasimoto Y, Kohri K, Ikeda K, and Nakanishi M (2000).
Induction of KAI-1 expression in metastatic cancer cells by phorbol esters. Can-
cer Lett 153, 79–83.
[16] Sigala S, Faraoni I, Botticini D, Paez-Pereda M, Missale C, Bonmassar E, and
Spano P (1999). Suppression of telomerase, re-expression of KAI1, and abroga-
tion of tumorigenicity by nerve growth factor in prostate cancer cell lines. Clin
Cancer Res 5, 1211–1218.
[17] Shinohara T, Miki T, Nishimura N, Nokihara H, Hamada H, and Mukaida
N (2001). Nuclear factor κB–dependent expression of metastasis suppressor
KAI1/CD82 gene in lung cancer cell lines expressing mutant p53. Cancer Res
61, 673–678.
[18] Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, and Somasundaram
K (2004). Expression profiling of sodium butyrate (NaB)–treated cells: identifi-
cation of regulation of genes related to cytokine signaling and cancer metastasis by
NaB. Oncogene 23, 6304–6315.
[19] Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, and
Chung LWK (1996). Suramin-induced decrease in prostate-specific antigen ex-
pression with no effect on tumor growth in the LNCaP model of human pros-
tate cancer. J Natl Cancer Inst 88, 794–801.
[20] Bauer A, Chauvet S, Huber O, Usseglio F, Rothbächer U, Aragnol D, Kemler R,
and Pradel J (2000). Pontin52 and Reptin52 function as antagonistic regulators
of β-catenin signalling activity. EMBO J 19, 6121–6130.
[21] Bauer A, Huber O, and Kemler R (1998). Pontin52, an interaction partner of
β-catenin, binds to the TATA box binding protein. Proc Natl Acad Sci USA 95,
14787–14792.
[22] Weiske J and Huber O (2005). The histidine triad protein Hint1 interacts with
Pontin and Reptin and inhibits TCF–β-catenin–mediated transcription. J Cell
Sci 118, 3117–3129.
[23] Weiske J, Albring KF, and Huber O (2007). The tumor suppressor Fhit acts as
a repressor of β-catenin transcriptional activity. Proc Natl Acad Sci USA 104,
20344–20349.
[24] Weiske J and Huber O (2006). The histidine triad protein Hint1 triggers apop-
tosis independent of its enzymatic activity. J Biol Chem 281, 27356–27366.
[25] Koivunen J, Aaltonen V, and Peltonen J (2006). Protein kinase C (PKC) family
in cancer progression. Cancer Lett 235, 1–10.
[26] Song JC, Hanson CM, Tsai V, Farokhzad OC, Lotz M, and Matthews JB
(2001). Regulation of epithelial transport and barrier function by distinct pro-
tein kinase C isoforms. Am J Physiol Cell Physiol 281, C649–C661.
[27] Clarke H, Ginanni N, Laughlin KV, Smith JB, Pettit GR, and Mullin JM (2000).
The transient increase of tight junction permeability induced by bryostatin 1 corre-
lates with rapid down-regulation of protein kinase Cα. Exp Cell Res 261, 239–249.
[28] Stewart JR and O’Brian CA (2005). Protein kinase C-α mediates epidermal
growth factor receptor transactivation in human prostate cancer cells. Mol Can-
cer Ther 4, 726–732.
[29] Hess A, Wijayanti N, Neuschäfer-Rube AP, Katz N, Kietzmann T, and
Immenschuh S (2003). Phorbol ester–dependent activation of peroxiredoxin I
gene expression via a protein kinase C, Ras, p38 mitogen-activated protein ki-
nase signaling pathway. J Biol Chem 278, 45419–45434.
[30] Hewson CA, Edbrooke MR, and Johnston SL (2004). PMA induces the
MUC5AC respiratory mucin in human bronchial epithelial cells, via PKC,
EGF/TGFα, Ras/Raf, MEK, ERK and Sp1-dependent mechanisms. J Mol Biol
344, 683–695.
Neoplasia Vol. 10, No. 12, 2008 Phorbol Ester Enhances KAI1 Transcription Rowe et al. 1431
[31] Lee HW, Ahn DH, Crawley SC, Li JD, Gum JR Jr, Basbaum CB, Fan NQ,
Szymkowski DE, Han SY, Lee BH, et al. (2002). Phorbol 12-myristate 13-
acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK,
and NF-κB. J Biol Chem 277, 32624–32631.
[32] Lee MH, Kim JY, and Anderson WB (2004). Src tyrosine kinase inhibitor PP2
markedly enhances Ras-independent activation of Raf-1 kinase by phorbol
myristate acetate and H2O2. J Biol Chem 279, 48692–48701.
[33] Ming XF, Burgering BMT, Wennstrom S, Claesson-Welsh L, Heldin CH, Bos
JL, Kozma SC, and Thomas G (1994). Activation of p70/p85 S6 kinase by a
pathway independent of rp21ras. Nature 371, 426–429.
[34] Tobin D, Nilsson M, and Toftgard R (1996). Ras-independent activation of
Rel-family transcription factors by UVB and TPA in cultured keratinocytes. On-
cogene 12, 785–793.
[35] Hazzalin CA and Mahadevan LC (2002). MAPK-regulated transcription: a con-
tinuously variable gene switch? Nat Rev Mol Cell Biol 3, 30–40.
[36] Lucas M, Zhang X, Prasanna V, and Mosser DM (2005). ERK activation fol-
lowing macrophage FcγR ligation leads to chromatin modifications at the IL-10
locus. J Immunol 175, 469–477.
[37] Pennini ME, Pai RK, Schultz DC, Boom WH, and Harding CV (2006).
Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-γ–induced chro-
matin remodeling of MHC2TA by TLR2 and MAPK signalling. J Immunol
176, 4323–4330.
[38] Clayton AL and Mahadevan LC (2003). MAP kinase–mediated phosphoacety-
lation of histone H3 and inducible gene regulation. FEBS Lett 546, 51–58.
[39] Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, and Rosenfeld MG (2002).
Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene
expression by NFκB and β-amyloid precursor protein. Cell 110, 55–67.
[40] Ho PD, Zechner DK, He H, Dillmann WH, Glembotski CC, and McDonough
PM (1998). The Raf-MEK-ERK cascade represents a common pathway for al-
teration of intracellular calcium by Ras and protein kinase C in cardiac myocytes.
J Biol Chem 273, 21730–21735.
[41] Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, and Ohno KS (1996). Protein
kinase C activates the MEK-ERK pathway in a manner independent of Ras and
dependent on Raf. J Biol Chem 271, 23512–23519.
[42] Wen-Sheng W (2006). Protein kinase C α trigger Ras- and Raf-independent
MEK/ERK activation for TPA-induced growth inhibition of human hepatoma
cell HepG2. Cancer Lett 239, 27–35.
[43] Clark SS, Zhong L, Filiault D, Perman S, Ren Z, Gould M, and Yang X (2003).
Anti-leukemia effect of perillyl alcohol in Bcr/Abl–transformed cells indirectly
inhibits signaling through Mek in a Ras- and Raf-independent fashion. Clin
Cancer Res 9, 4494–4504.
[44] Marreiros A, Dudgeon K, Dao V, GrimmMO, Czolij R, CrossleyM, and Jackson
P (2005). KAI1 promoter activity is dependent on p53, junB and AP2: evidence
for a possible mechanism underlying loss of KAI1 expression in cancer cells. On-
cogene 24, 637–649.
[45] Perissi V and Rosenfeld MG (2005). Controlling nucelar receptors: the circular
logic of cofactor cycles. Nat Rev Mol Cell Biol 6, 542–554.
[46] Sierra J, Yoshida T, Joazeiro CA, and Jones KA (2006). The APC tumor sup-
pressor counteracts β-catenin activation and H3K4 methylation at Wnt target
genes. Genes Dev 20, 586–600.
[47] Baek SH (2006). A novel link between SUMO modification and cancer metas-
tasis. Cell Cycle 5, 1492–1495.
[48] Cheng J, Bawa T, Lee P, Gong L, and Yeh ETH (2006). Role of desumoylation
in the development of prostate cancer. Neoplasia 8, 667–676.
[49] Kim JH, Lee JM, NamHJ, Choi HJ, Yang JW, Lee JS, KimMH, Kim SI, Chung
CH, Kim KI, et al. (2007). SUMOylation of pontin chromatin-remodeling com-
plex reveals a signal integration code in prostate cancer. Proc Natl Acad Sci USA
104, 20793–20798.
[50] Gallant P (2007). Control of transcription by Pontin and Reptin. Trends Cell
Biol 17, 187–192.
[51] Huber O and Weiske J (2008). β-Catenin takes a HIT. Cell Cycle 7, 1326–1331.
[52] Huber O, Ménard L, Haurie V, Nicou A, Taras D, and Rosenbaum J (2008).
Pontin and Reptin, two related ATPases with multiple roles in cancer. Cancer Res
68, 6873–6876.
[53] Lauscher JC, Loddenkemper C, Kosel L, Gröne J, Buhr HJ, and Huber O
(2007). Increased pontin expression in human colorectal cancer tissue. Hum
Pathol 38, 978–985.
[54] Rousseau B, Ménard L, Haurie V, Taras D, Blanc JF, Moreau-Gaudry F, Metzler
P, Hugues M, Boyault S, Lemière S, et al. (2007). Overexpression and role of
the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular
carcinoma. Hepatology 46, 1108–1118.
[55] Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang
J, Mehra R, Keller ET, et al. (2008). An in vivo mouse model for human pros-
tate cancer metastasis. Neoplasia 10, 371–379.
1432 Phorbol Ester Enhances KAI1 Transcription Rowe et al. Neoplasia Vol. 10, No. 12, 2008
Figure W1. Phorbol 12-myristate 13-acetate up-regulates KAI1 mRNA levels in DU145 and PC3 prostate cancer cells. (A) Cells were
untreated (C), treated with DMSO vehicle only for 24 hours (V), or treated with the indicated concentrations of PMA for 24 hours.
KAI1 and GAPDHmRNA levels were determined from total RNA by RT-PCR. (B) Cells were treated with DMSO vehicle only (V) or treated
with 20 nM PMA for the indicated times. KAI1 and GAPDHmRNA levels were determined from total RNA by RT-PCR. Upper panels in (A)
and (B) show ethidium bromide–stained gels of representative data. Lower panels show the relative levels of KAI1 mRNA (KAI1/GAPDH)
in treated cells. Data for DU145 represent the mean ± SD of at least three independent experiments (*P < .05, when compared with
vehicle only–treated cells), and for PC3, the mean of two independent experiments.
